Iberdomide
CELMoDs are here, but are they here to stay? CELMoD/IMiD review article: https://doi.org/10.1080/17474086.2024.2382897 Download the Oncology...
Radio and PodcastLive Radio & Podcasts
Science & Medicine
OncoPharm
Oncology Pharmacist & Educator. Talking all things #oncopharm
OncoPharm Podcast Guide
Listen to OncoPharm, a Science & Medicine podcast by OncoPharmPod. Stream 439 episodes in English, follow new audio stories, and play episodes online on Radio and Podcast.
Show Topic
Browse this show under Science & Medicine podcasts.
Episodes
20 episodes are loaded now from a catalog of 439. More episodes can be opened from this page.
Discover More
Explore Science & Medicine podcasts, India podcasts and English podcasts.
Episodes
20 of 439 episodesKidney Cancer in a Nutshell
Overview of renal cell carcinoma Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Small Cell Lung Cancer and CINV Updates
This week's episode covers some updates in small cell lung cancer, chemotherapy-induced nausea/vomiting (CINV), SC administration of isatuxi...
Zidesamtinib & PPIs in Pacific
A new drug is approved for ROS1 NSCLC after a prior TKI (with some data in patients after 2 TKIs). Zidesamtinib...easy for you to say. Also,...
Gedatolisib et al
This week's pod covers some brief updates comparing the timelines of the FDA approvals for daraxonrasib vs. enfortuamb vedodin + pembrolizum...
Endurance Part 2
Did lenalidomide maintenance in multiple myeloma just get limited to 2 years? Endurance Trial, Part 2: https://www.nejm.org/doi/full/10.1056...
A Decade of CAR-T, Ocra-T, & POLARGO
We are a decade into the CAR-T era, and what to long term outcomes look like with tisagenlecleucel in B-cell lymphomas? Orca-T is approved,...
Breast Cancer Updates and T-Cell Stemness
This week we discuss a new approval for pabociclib in HER2-positive disease based on the PATINA trial as well as the use of sacituzumab govi...
Updates on capivasertib, belzutifan, talquetamab, & durvalumab
Lots of bite-size updates in this episode. Capitello-281: capivasertib + abiraterone (+ prednisone + ADT) Adjuvant Belzutifan + Pemroblizuma...
ASCO '26
ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list: 1. RASolute 302 - daraxonrasib and its standing ova...
Pivekimab sunirine
Pivekimab sunirine, a novel CD-123 antibody drug conjugate is approved for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Also, what...
BCL2 & HER2 Targeting Agent Updates
The FDA has been a bunch of busy bees with new approvals: 1. Sonrotoclax, an exciting new BCL2 inhibitor approved for 3rd-line Mantle Cell L...
IMHOTEP, PJP, and more
This week's pod has lots of updates! IMHOTEP: Pre-operative doses of pembrolizumab lead to significant pCR rates in dMMR colon cancer. https...
Vepdegestrant
The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that a...
Targets Trop 2
This is our 1st in a series of podcasts/videos to role out once or twice a year on therapeutic targets in cancer. First up - Trop2 Check out...
Promising Pancreatic Cancer Data
This week we highlight some promising clinical research in the pancreatic cancer space. Daraxonrasib has shown OS benefit vs. chemo in the 2...
ICI-Induced T1DM
Bibliography: 1.. 2019 Systematic Review of Published Cases: https://doi.org/10.1111/dme.14050 2. Mass General Data & Publication: https://j...
Relacorilant
Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer. As a glucoCORticoid receptor antagonist, it is ha...
HOPA 2026 Recap
Recapping what I learned at HOPA 2026: -Beyond steroids for irAs -IT chemo beyond methotrexate and cytarabine -Pre-emptive CMV management in...
Nivo-AVD Approval
Nivolumab-AVD is finally approved for Hodgkin Lymphoma, and primary G-CSF prophylaxis is recommended (?) in the PI. Also, brief NOLA preview...